Categories: News

Invitation to Conference Call Regarding Promore Pharma’s Interim Report for the First Quarter 2022

STOCKHOLM, SWEDEN / ACCESSWIRE / May 13, 2022 / Promore Pharma (STO:PROMO)(FRA:8T0)

STOCKHOLM, 13 May 2022 – Promore Pharma AB (publ) publishes its interim report for the first quarter 2022 on 17 May 2022.

The same day the company will host a webcast telephone conference at 16.00 CET, with President and CEO Jonas Ekblom and CFO Erik Magnusson, where an update for the quarter and upcoming activities. After the presentation there will be a Q&A session. The conference call will be held in English and can be accessed via computer, tablet, or telephone.

The number of attendees is limited, please register for the conference in advance on the following link:

https://attendee.gotowebinar.com/register/4045498425908535564

The conference call will be recorded and made available on the company´s website after the call, and on Västra Hamnen Corporate Finance Youtube channel.

About Promore Pharma

Promore Pharma is a biopharmaceutical company that develops pharmaceutical product candidates for bioactive wound care. Today, the company has two drug candidates in late clinical development stages, that are based on endogenous peptides, and thus have a strong safety profile. These two products are intended for treatment of chronic wounds, and prevention of scarring on the skin and other tissues. The company is listed on the Nasdaq First North Growth Market.

For additional information, please contact

Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com

Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com

Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: certifiedadviser@penser.se

Attachments

Invitation to Conference Call regarding Promore Pharma’s Interim Report for the First Quarter 2022

SOURCE: Promore Pharma

View source version on accesswire.com:
https://www.accesswire.com/701250/Invitation-to-Conference-Call-Regarding-Promore-Pharmas-Interim-Report-for-the-First-Quarter-2022

Staff

Recent Posts

NextGen Healthcare Chosen by United Medical Centers to Support Integrated Care Delivery in Communities at United States-Mexico Border

Growing Need for Integration Led FQHC to Select NextGen HealthcareREMOTE-FIRST COMPANY/EAGLE PASS, Texas--(BUSINESS WIRE)--#NextGenHealthcare--Driven by…

54 mins ago

The Assistance Fund Opens New Program for Heart Failure

Copay Assistance From The Assistance Fund Now Available for Eligible People Living With Heart FailureORLANDO,…

56 mins ago

US Med-Equip Earns CIO 100 Award for IT Innovation With New AI Solution Helping Clinicians Secure Medical Equipment on Demand

Life-Saving Equipment Delivered to Patients in Record Time, Lower Cost at Hospitals Using Award-Winning GoUSME…

56 mins ago

Zeto Successfully Completes SOC 2 Type II Audit for Its Cloud Platform, Demonstrating Commitment to Data Security

SANTA CLARA, CA / ACCESSWIRE / March 18, 2024 / Zeto, Inc., a commercial-stage medical…

56 mins ago

Sona Nanotech Announces Filing of Provisional Patent Application

Halifax, Nova Scotia--(Newsfile Corp. - March 18, 2024) - Sona Nanotech Inc. (CSE: SONA), (OTCQB:…

3 hours ago